Ondansetron Kalceks

Ondondansetron, the active ingredient in Ondansetron Kalceks, is a 5-HT3 receptor antagonist presented as a 5 mg tablet for oral use. It treats and prevents nausea and vomiting associated with chemotherapy, radiation therapy, and surgery in adult patients. GNH USA supplies Ondansetron Kalceks as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

GNH USA supplies Ondansetron Kalceks as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Ondansetron Kalceks is a selective 5‑HT3 receptor antagonist that reduces nausea and vomiting in several clinical settings.

- Chemotherapy‑induced nausea and vomiting: Helps prevent and control CINV by blocking serotonin signals in the chemoreceptor trigger zone. - Radiation‑induced nausea and vomiting: Reduces the incidence of RINV by antagonising peripheral 5‑HT3 receptors. - Post‑operative nausea and vomiting: Decreases the frequency of PONV through central 5‑HT3 blockade. - Hyper‑emesis gravidarum (off‑label use): May allev symptoms when standard therapies are insufficient. - Nausea due to other causes: Provides symptomatic relief in various situations where serotonin‑mediated nausea occurs.

Common Side Effects: - Headache: mild to moderate intensity. - Constipation: occasional bowel movement reduction. - Diarrhoea: transient loose stools. - Fatigue: general tiredness. - Dizziness: brief episodes of light‑headedness. - Injection site pain (if administered parenterally): mild discomfort.

Serious or Rare Side Effects: - QT interval prolongation: may predispose to cardiac arrhythmias. - Severe allergic reaction: rash, itching, swelling, or anaphylaxis. - Serotonin syndrome: rare when combined with other serotonergic agents. - Hepatic dysfunction: elevated liver enzymes. - Severe constipation or intestinal obstruction. - Neuroleptic malignant‑like syndrome: extremely rare neurological emergency.

Ondansetron should be used with caution in patients with known cardiac rhythm disorders or electrolyte imbalances.

- Cardiac monitoring: obtain baseline ECG in patients with risk factors for QT prolongation. - Electrolyte assessment: correct hypokalaemia or hypomagnesemia before therapy. - Drug‑interaction review: evaluate concurrent serotonergic medications. - Pregnancy: use only if the potential benefit outweighs the risk. - Breastfeeding: consider infant exposure; monitor for adverse effects. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Ondansetron may interact with several drug classes, altering its efficacy or safety profile.

Major Interactions (Avoid): - Apomatinib?   -    -   t   -   -  t .

Moderate  g  t.

-  t. -  t. -  t. -  t.